

IsoRay, Inc.  
Form 8-K  
May 08, 2018

**United States Securities And Exchange Commission  
Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): May 8,  
2018

**ISORAY, INC.**

(Exact name of registrant as specified in its charter)

**Minnesota**

**001-33407**

**41-1458152**

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

**350 Hills Street, Suite 106, Richland, Washington 99354**

(Address of principal executive offices) (Zip Code)

**(509) 375-1202**

(Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01** *Entry into a Material Definitive Agreement.*

On May 8, 2018, IsoRay, Inc., a Minnesota corporation (the “Company”), entered into a Sales Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”). Pursuant to the terms of the Agreement, the Company may offer and sell (the “Offering”) from time to time through Wainwright, as the Company’s sales agent, up to \$8.5 million of shares of the Company’s common stock, par value \$0.001 per share (the “Shares”). Sales of the Shares, if any, may be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Wainwright is not required to sell any specific number or dollar amount of Shares, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Wainwright and the Company. Wainwright will receive from us a commission of 3.0% of the gross proceeds from the sales of Shares pursuant to the terms of the Agreement. Net proceeds from the sale of the Shares will be used for general corporate purposes. The Company has also agreed to reimburse Wainwright for certain expenses incurred in connection with the Agreement, including fees and disbursements of counsel to Wainwright in connection with entering into the transactions contemplated by the Agreement up to \$50,000 and quarterly disbursements of counsel to Wainwright up to \$2,500 per calendar quarter, and has provided Wainwright with customary indemnification rights.

The offering of Shares pursuant to the Agreement will terminate upon the earliest of (i) the sale of all Shares subject to the Agreement, and (ii) the termination of the Agreement by the Company or Wainwright.

The Shares will be issued pursuant to the Company’s shelf registration statement (the “Registration Statement”) on Form S-3 (File No. 333-206559) filed on August 25, 2015, as amended by Amendment No. 1 filed on October 9, 2015, and Amendment No. 2 filed on November 19, 2015, which became effective on November 23, 2015, and the prospectus supplement dated May 8, 2018.

The Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the description of the Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Gallagher & Kennedy, P.A., relating to the legality of the Shares is filed as Exhibit 5.1 hereto, and is incorporated herein by reference. The foregoing description of the Offering by the Company and the documents related thereto is qualified in its entirety by reference to such exhibits.

**Item 9.01** *Financial Statements and Exhibits.*

(d) Exhibits

5.1 Opinion of Gallagher & Kennedy, P.A., dated May 8, 2018.

10.1 Sales Agreement between IsoRay, Inc. and H.C. Wainwright & Co., LLC, dated May 8, 2018.

23.1 Consent of Gallagher & Kennedy, P.A. (included in Exhibit 5.1).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 8, 2018

IsoRay, Inc., a Minnesota corporation

By: /s/ Mark Austin

T Mark Austin, Controller, Principal Financial & Accounting Officer